Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.
Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.
Buys established over-the-counter brands that larger companies treat as too small, outsources almost all manufacturing to contract makers, and spends on advertising to hold shelf space. Walmart is its largest customer. Sales are mostly in North America, with smaller bases in Australia and elsewhere.
Moat: narrow (brand, distribution). Long-established OTC brand names hold trusted shelf space that is hard for new entrants to win.
Headquarters: Tarrytown, New York, US · Founded: 1996 · Employees: 890
Size Prestige Consumer Healthcare (PBH) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.40B, the 1666th largest of 3,085 United States companies the cockpit tracks. Shares closed at $50.62 on 18 Nov 2026.
Performance Over six months the shares gained 7.3%, against -11.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 5.1% over the last twelve months (peer median +4.2%); the operating margin is 24.9% (peer median 9.1%).
Valuation It trades at 10.6× forward earnings against a peer median of 27.3× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (6.1% WACC).
Short interest Short interest is 8.9% of the free float (30 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.09B | $1.14B | $1.13B | $1.13B |
| Revenue growth | — | -4% | +1% | 0% | — |
| Gross profit | $587M | $575M | $613M | $602M | $600M |
| EBITDA | $328M | $341M | $379M | $373M | $387M |
| Net income | $155M | $190M | $215M | $209M | -$82.3M |
| Free cash flow | $214M | $246M | $243M | $239M | $222M |
| Capital expenditure | $15.6M | $11.2M | $8.22M | $9.55M | $7.78M |
| Total debt | $2.13B | $1.05B | $1.04B | $1.14B | $1.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare PBH | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
| Haleon HLN.L | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% |
| Church & Dwight CHD | $26.4B | +16% | +2% | 18% | 28.1× | 7.7% |
| Reckitt Benckiser RKT.L | $47.5B | +22% | -2% | 28% | 16.7× | 2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -5.5% | 3rd highest of 21 |
| 6-month return | +7.3% | -11.5% | 7th highest of 21 |
| Distance from 52-week high | -28.8% | -33.1% | 11th highest of 21 |
| Revenue growth (TTM) | +5.1% | +4.2% | 10th highest of 20 |
| Operating margin | 24.9% | 9.1% | 3rd highest of 19 |
| Forward P/E | 10.6× | 27.3× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 2.3% | 18.7% | 5th least demanding of 15 |
| Growth delivered (Del g) | +2.9% | +6.5% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -0.6 pp | +6.3 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | -0.4 pp | -2.2 pp | 6th highest of 15 |
| EV / EBITDA | 13.7× | 9.5× | 2nd most expensive of 5 |
| Net debt / EBITDA | 6.3× | -0.1× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |